ANGIOTENSIN–NEPRILYSIN INHIBITION IN DIASTOLIC DYSFUNCTION AFTERAMI

Odense University Hospital0 个研究点目标入组 100 人开始时间: 2018年5月18日最近更新: 2024年2月19日

适应症

试验速览

暂无简介。

•Key inclusion criteria:
•1. Documented ST segment or non ST segment elevation AMI,
•2. Complete revascularization.
•3. Age >=50 years
•4. LVEF >=45% on echocardiography performed within 72 hours of the AMI.
•5. Diastolic dysfunction defined as: Ratio of early diastolic peak mitral inflow velocity (E) to early mitral annulus diastolic velocity (e’) ratio > 8 and LA dilatation (LA volume
•index>34 mL/m2).
•6. Signed informed consent
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 34
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 66

•1. Known history of cardiomyopathy, and or moderate/severe valvular heart disease,
•2. Severe obstructive or restrictive pulmonary disease,
•3. Inability to perform exercise testing/ inadequate acoustic windows on echocardiography,
•4. Class I indication for an angiotensin converting enzyme inhibitor.
•5. A systolic blood pressure of less than 100 mm Hg at screening
•6. An estimated glomerular filtration rate (eGFR) below 30 ml per minute per 1.73 m2 of
•body-surface area at any time,
•7. A serum potassium level of more than 5.2 mmol per liter at screening,
•8. A history of angioedema or unacceptable side effects during receipt of angiotensin
•converting enzyme inhibitor or angiotensin receptor blocker
•9. Inability to provide informed consent

发起方